


## Cinobufotalin Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)**[ Product Information ]****Name:** Cinobufotalin**Catalog No.:** CFN90137**Cas No.:** 1108-68-5**Purity:** >=98%**M.F:** C<sub>26</sub>H<sub>34</sub>O<sub>7</sub>**M.W:** 458.54**Physical Description:** Powder**Synonyms:** 5-beta-Bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-, 16-acetate; (3beta,5beta,15beta,16beta)-16-(acetyloxy)-3,5-dihydroxy-14,15-epoxybufa-20,22-dienolide.**[ Intended Use ]**

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

**[ Source ]**The glandular body of *Bufo bufo gargarizans* Cantor.

## **[ Biological Activity or Inhibitors ]**

Cinobufotalin (CB), one of the bufadienolides prepared from toad venom, it induces caspase dependent cell death in U937 cells, and that Fas plays a role in CB-induced apoptosis, it has potential as a future chemotherapeutic agent.<sup>[1]</sup>

Cinobufotalin is a main cardiac toxin in toad.<sup>[2]</sup>

Cinobufotalin can inhibit A549 lung cancer cell growth in vivo, mainly by inducing Cyp-D-dependent non-apoptotic death, suggests that cinobufotalin may be further investigated as a novel anti-lung cancer agent. <sup>[3]</sup>

Cinobufotalin can promote the dendritic cells(DCs) derived from peripheral blood of patients with chronic hepatitis B to mature and effectively enhance its(the DCs') capabilities, therefore the treatment of cinobufotalin may potentiate the antiviral immunity of the patients with chronic hepatitis B(CHB).<sup>[4]</sup>

## **[ Solvent ]**

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

## **[ HPLC Method ]**<sup>[5]</sup>

Mobile phase: Acetonitrile-H<sub>2</sub>O=48:52 ;

Flow rate: 0.8 ml/min;

Column temperature: 30 °C;

The wave length of determination: 296 nm.

## **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

[1] Emam H, Zhao Q L, Furusawa Y, *et al. Chem.Biol. Int.*, 2012, 199(3):154-60.

[2] Dasgupta A, Emerson L. *Life Sci.*, 1998, 63(9):781-8.

[3] Kai S, Lu J H, Hui P P, *et al. Biochem. Bioph. Res.Co.*, 2014, 452(3):768-74.

[4] Wei X, Wang X, Tang W. *Pharmacology & Clinics of Chinese Materia Medica*, 2007, 23(4):54-6.

[5] Wang Y G, Gu S L. *Chinese Journal of Pharmaceutical Analysis*, 2009,29(7):1172-4.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)